cue the lightning bolts

the only question that matters: is it true?

Iran has signed the NPT. As a signatory to the NPT, Iran may rightfully, legally, use nuclear technology for peaceful energy purposes. Iran has submitted to and passed repeated IAEA inspections. The US intelligence community (NIE) does not consider Iran a nuclear threat. Israel refuses to sign the NPT. Israel has an estimated several hundred undeclared nuclear weapons. Russia and China have warned that an attack on Iran will have global consequences. That's the situation in a nutshell. Where to next, people? Where to?

Have I now become your enemy by telling you the truth? - Galatians 4:16


OK OK OK, time out...let's get them to agree to *one* shot. allright? allright.

Sept. 10, 2009 - Adults are immune to swine flu after just one shot of vaccine, early test results suggest. It's a surprise finding. Most experts expected that two shots of the vaccine -- given three weeks apart -- would be needed.

Now vaccine supplies may go twice as far, and may start working twice as fast as expected, suggests University of Washington researcher Kathleen M. Neuzil, MD, MPH, chairwoman of the flu vaccine working group of the Advisory Committee on Immunization Practices (ACIP), the independent panel that recommends vaccine policy to the CDC.

"On the basis of these data, it would be appropriate to begin vaccination with the use of one dose," Neuzil writes in an editorial accompanying a report of the study rushed into online publication by The New England Journal of Medicine.

Neuzil, a pediatrician, notes that children may still need two doses of the vaccine. But she says vaccine supplies "should not be held in reserve to be used for a second dose."

read more @ web md

FACTBOX: biotech companies benefitting from flu outbreak

(Reuters) - Here is a list of biotech companies whose shares may rise or fall depending on the course of the swine flu pandemic.

* GILEAD SCIENCES INC - Receives royalties on sales of the Tamiflu pill, which Roche Holding AG sells under license from Gilead. According to analysts at Barclays Capital, current projections for the second half of the year suggest combined seasonal and pandemic Tamiflu sales of $1 billion.

* BIOTA HOLDINGS LTD - The Australian biotech company receives royalties on sales of the inhaled antiviral drug Relenza, which is marketed by GlaxoSmithKline Plc. Biota's royalties more than doubled to $37.5 million in the year to June. The company is developing a new flu drug, laninamivir, with Daiichi Sankyo. Late stage studies in Asia showed a single dose of inhaled laninamivir alleviated flu as effectively as five days of twice-daily Tamiflu.

* NOVAVAX INC - Will apply to U.S. Food and Drug Administration in the fourth quarter to start human clinical trials of its H1N1 vaccine. An earlier trial of the virus-like particle (VLP) vaccine showed it protected ferrets from swine flu. The vaccines can be grown in caterpillar cells and can be produced much quicker than traditional vaccines made using chicken eggs.

* BIOCRYST PHARMACEUTICALS INC - Has intravenous antiviral called peramivir in late stage development. A late-stage trial sponsored by partner Shionogi & Co Ltd of Japan showed peramivir was no less effective than Tamiflu.

* VICAL INC - Developing a gene-based vaccine using its Vaxfectin adjuvant, which boosts the immune system. Early trials showed it produced a robust immune responses in animals. The company is developing vaccines against the H5N1 avian flu strain and the new H1N1 virus.

* INOVIO BIOMEDICAL CORP - Developing DNA-based H1N1 flu vaccines that protect pigs and mice. It will jointly develop universal influenza vaccines -- vaccines that target several strains of the virus -- with the National Institutes of Health's research unit.

* MEDICAGO INC - The Canadian biotech makes protein-based vaccines through the genetic engineering of plants such as tobacco. It is working to form agreements in different geographies. Most recently, it said it expects to sign a licensing agreement with a Middle East company that will pave the way for the say for the development of its swine flu vaccine in the region.

* GENEREX BIOTECHNOLOGY CORP - Making synthetic peptide vaccines. These differ from egg-based vaccines in that they do not use a live virus. Instead, peptides are arranged so as to mimic the virus, priming the immune system. The vaccines are designed to be produced more quickly than traditional vaccines. Generex will apply to U.S. regulators in the fourth-quarter to start human trials.

* CRUCELL NV - The Dutch biotech plans to begin clinical trials of its experimental antibody-based flu drug mAB CR6261 next year. The company's PER.C6 technology uses human cells rather than chicken eggs to produce an antibody to prevent a infection with a variety of flu viruses.

* CSL Ltd - Australia's CSL has completed its first batch of 2 million shots in 15 microgram doses and is producing up to 1.5 million doses per week until it fills orders, which include an order for 21 million doses from the Australian government and $180 million in orders from the United States.

* GREEN CROSS - Green Cross, the only South Korean drug company that can mass produce an H1N1 flu vaccine, has signed a $7.4 million supply deal with the government, which secured 1.1 million doses of the vaccine for delivery by the end of November.

* SINOVAC BIOTECH LTD - The China-based company is the first worldwide to complete clinical trials of an H1N1 flu vaccine. It said the vaccine, which is given in a single dose, rather than the two doses typical for a vaccine, is ready for delivery. Sinovac expects to produce 30 million doses.

* HUALAN BIOLOGICAL - A Chinese panel of experts has given the green light to the Shanghai-listed company's vaccine. It is expected to be approved there this month.

(Reporting by Toni Clarke; Editing by Maggie Fox, Gary Hill)


I'm sure all the conflicts of interest in the cozy little world of big pharma/CDC/health care have been disclosed, aren't you?

No comments:

legal mumbo jumbo

Disclaimer: The posting of stories, commentaries, reports, documents and links (embedded or otherwise) on this site does not in any way, shape or form, implied or otherwise, necessarily express or suggest endorsement or support of any of such posted material or parts therein.

Fair Use: This site contains copyrighted material the use of which has not always been specifically authorized by the copyright owner. We are making such material available in our efforts to advance understanding of environmental, political, human rights, economic, democracy, scientific, and social justice issues, etc. We believe this constitutes a 'fair use' of any such copyrighted material as provided for in section 107 of the US Copyright Law. In accordance with Title 17 U.S.C. Section 107, the material on this site is distributed without profit to those who have expressed a prior interest in receiving the included information for research and educational purposes. If you wish to use copyrighted material from this site for purposes of your own that go beyond 'fair use', you must obtain permission from the copyright owner.